Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer?

European Journal of Cancer

Volumn 42, Issue 6, 2006, Pages 785-792

  Assenat, Eric ^a,b,c   Gerbal chaloin, Sabine ^b   Maurel, Patrick ^b,c   Vilarem, Marie José ^b,c   Pascussi, Jean Marc ^b,c  

^a HÔPITAL SAINT ELOI   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Cancer; Cytochrome P450; Drug metabolism; Inflammation

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CHEMOSENSITIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; GENE CONTROL; GENETIC VARIABILITY; HUMAN; INFLAMMATION; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION; HUMANS; INFLAMMATION; LIVER; NEOPLASMS; NF-KAPPA B;

EID: 33646010938     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.005     Document Type: Article

References (93)

1. Kivisto K.T., Kroemer H.K., and Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40 6 (1995) 523-530
2. Roy P., et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27 6 (1999) 655-666
3. Kan O., et al. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther 8 7 (2001) 473-482
4. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52 4 (2001) 349-355
5. Rendic S., and Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29 1-2 (1997) 413-580
6. Mahmoud F.A., and Rivera N.I. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4 3 (2002) 250-255
7. Martin F., et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11 1 (1999) 80-86
8. Barber M.D., Fearon K.C., and Ross J.A. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci (Lond) 96 1 (1999) 83-87
9. Heys S.D., et al. Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival. Int J Oncol 13 3 (1998) 589-594
10. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 6917 (2002) 860-867
11. Morgan E.T. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29 4 (1997) 1129-1188
12. Roy-Chowdhury J., Locker J., and Roy-Chowdhury N. Nuclear receptors orchestrate detoxification pathways. Dev Cell 4 5 (2003) 607-608
13. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 9255 (2001) 539-545
14. Piancatelli D., et al. Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J Immunother 22 1 (1999) 25-32
15. Kinoshita T., Ito H., and Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85 12 (1999) 2526-2531
16. Munger K. The role of human papillomaviruses in human cancers. Front Biosci 7 (2002) d641-d649
17. Gerhard M., et al. Pathogenesis of Helicobacter pylori infection. Helicobacter 7 Suppl. 1 (2002) 17-23
18. Hilleman M.R. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 21 32 (2003) 4626-4649
19. Rosin M.P., Anwar W.A., and Ward A.J. Inflammation, chromosomal instability, and cancer: the schistosomiasis model. Cancer Res 54 Suppl. 7 (1994) 1929s-1933s
20. Manning C.B., Vallyathan V., and Mossman B.T. Diseases caused by asbestos: mechanisms of injury and disease development. Int Immunopharmacol 2 2-3 (2002) 191-200
21. Mantovani G., et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 98 1 (2002) 84-91
22. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 6 (1999) 448-454
23. Castell J.V., et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12 5 (1990) 1179-1186
24. Schwartsburd P.M. Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metast Rev 22 1 (2003) 95-102
25. Slaviero K.A., Clarke S.J., and Rivory L.P. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 4 4 (2003) 224-232
26. Barnes P.J., and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 15 (1997) 1066-1071
27. Ghosh S., May M.J., and Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16 (1998) 225-260
28. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell Suppl. 109 (2002) S81-S96
29. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18 (2000) 621-663
30. Li Z.W., et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189 11 (1999) 1839-1845
31. Senftleben U., et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293 5534 (2001) 1495-1499
32. Dejardin E., et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17 4 (2002) 525-535
33. Ben-Neriah Y., and Schmitz M.L. Of mice and men. EMBO Rep 5 7 (2004) 668-673
34. Chen L.W., et al. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 9 5 (2003) 575-581
35. Karin M., et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2 4 (2002) 301-310
36. Hacker H., and Karin M. Is NF-kappaB2/p100 a direct activator of programmed cell death?. Cancer Cell 2 6 (2002) 431-433
37. Gilmore T.D. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 18 49 (1999) 6842-6844
38. Sun S.C., and Xiao G. Deregulation of NF-kappaB and its upstream kinases in cancer. Cancer Metast Rev 22 4 (2003) 405-422
39. Amit S., and Ben-Neriah Y. NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 13 1 (2003) 15-28
40. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 3 3 (2002) 221-227
41. Balkwill F., and Coussens L.M. Cancer: an inflammatory link. Nature 431 7007 (2004) 405-406
42. Pikarsky E., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 7007 (2004) 461-466
43. Greten F.R., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 3 (2004) 285-296
44. Rogler G., et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115 2 (1998) 357-369
45. Lind D.S., et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 130 2 (2001) 363-369
46. Yu H.G., et al. Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology 65 1 (2003) 37-45
47. Yu H.G., et al. Increased expression of nuclear factor-kappaB/RelA is correlated with tumor angiogenesis in human colorectal cancer. Int J Colorectal Dis 19 1 (2004) 18-22
48. Block T.M., et al. Molecular viral oncology of hepatocellular carcinoma. Oncogene 22 33 (2003) 5093-5107
49. Dogra S.C., Khanduja K.L., and Sharma R.R. Hepatic drug-metabolizing enzymes in lung tumor-bearing rats. Biochem Pharmacol 34 17 (1985) 3190-3193
50. Maliakal P.P., Coville P.F., and Wanwimolruk S. Decreased hepatic drug metabolising enzyme activity in rats with nitrosamine-induced tumours. Drug Metabol Drug Interact 19 1 (2002) 13-27
51. Philip P.A., et al. Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man. Int J Radiat Oncol Biol Phys 29 2 (1994) 277-283
52. Schmidt R., et al. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br J Cancer 90 4 (2004) 911-916
53. Lechevrel M., et al. Characterization of cytochrome P450 expression in human oesophageal mucosa. Carcinogenesis 20 2 (1999) 243-248
54. Massaad L., et al. Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems. Cancer Res 52 23 (1992) 6567-6575
55. Huang Z., et al. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24 8 (1996) 899-905
56. Rivory L.P., Slaviero K.A., and Clarke S.J. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87 3 (2002) 277-280
57. Baker S.D., et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10 24 (2004) 8341-8350
58. Chen Y.L., et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 55 6 (1994) 649-660
59. Moore L.B., et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275 20 (2000) 15122-15127
60. Maglich J.M., et al. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62 3 (2002) 638-646
61. Pascussi J.M., et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 274 3 (2000) 707-713
62. Beigneux A.P., et al. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophys Res Commun 293 1 (2002) 145-149
63. Teng S., and Piquette-Miller M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J Pharmacol Exp Ther 312 2 (2005) 841-848
64. Pascussi J.M., et al. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58 2 (2000) 361-372
65. Pascussi J.M., et al. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 58 6 (2000) 1441-1450
66. Pascussi J.M., et al. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268 24 (2001) 6346-6358
67. Beato M., Herrlich P., and Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 83 6 (1995) 851-857
68. Adcock I.M. Glucocorticoid-regulated transcription factors. Pulm Pharmacol Ther 14 3 (2001) 211-219
69. Pascussi J.M., et al. Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol Endocrinol 17 1 (2003) 42-55
70. Assenat E., et al. Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology 40 4 (2004) 951-960
71. Scheinman R.I., et al. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 15 2 (1995) 943-953
72. Heck S., et al. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J 16 15 (1997) 4698-4707
73. Nissen R.M., and Yamamoto K.R. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 14 18 (2000) 2314-2329
74. Ito K., et al. p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex. J Biol Chem 276 32 (2001) 30208-30215
75. Perez P., et al. Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. FASEB J 15 11 (2001) 2030-2032
76. Budunova I.V., et al. Glucocorticoid receptor functions as a potent suppressor of mouse skin carcinogenesis. Oncogene 22 21 (2003) 3279-3287
77. Reichardt H.M., et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 20 24 (2001) 7168-7173
78. Tuckermann J.P., et al. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol 147 7 (1999) 1365-1370
79. Sheppard K.A., et al. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 273 45 (1998) 29291-29294
80. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 29 Suppl. 1 (2003) 33-39
81. Milligan S.A., and Nopajaroonsri C. Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro. Anticancer Res 21 1A (2001) 39-44
82. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3 1 (2004) 17-26
83. Eaden J., et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 14 2 (2000) 145-153
84. Kopp E., and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265 5174 (1994) 956-959
85. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 6706 (1998) 77-80
86. Gupta R.A., and Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1 1 (2001) 11-21
87. Shishodia S., Koul D., and Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173 3 (2004) 2011-2022
88. Seitz C.S., et al. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA 95 5 (1998) 2307-2312
89. Brown J.M., and Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58 7 (1998) 1408-1416
90. Jounaidi Y., and Waxman D.J. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 60 14 (2000) 3761-3769
91. Zhou G., and Kuo M.T. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem 272 24 (1997) 15174-15183
92. Bentires-Alj M., et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22 1 (2003) 90-97
93. Michael M., and Doherty M.M. Tumoral drug metabolism: overview and its implications for cancer therapy. J Clin Oncol 23 1 (2005) 205-229